Simple Summary In oncology, treatment outcomes can be competing, which means that one
treatment could benefit one outcome, like survival, and negatively influence another, like …

Objectives The main objectives of this article are 2-fold. First, we explore the application of
multicriteria decision analysis (MCDA) methods in different areas of health care, particularly …

In this paper we consider a combination therapy of cancer. One drug is a vaccine which
activates dendritic cells so that they induce more T cells to infiltrate the tumor. The other drug …

Background The landscape of clinical trials testing risk-adapted modulations of cancer
treatments is complex. Multiple trial designs, endpoints, and thresholds for non-inferiority …

In order to explore the potential of immune checkpoint blockade in sarcoma, we investigated
expression and clinical relevance of programmed cell death-1 (PD-1), programmed death …

Objective The aim of this study was to determine the smallest worthwhile effects of two
treatments for nonspecific low back pain (LBP). Study Design and Setting The benefit–harm …

Background The aim of this paper is twofold:(1) to describe the fundamental differences
between formative and reflective measurement models, and (2) to review the options …

Objectives: Inclusion of patient preference (PP) data in decision making has been largely
discussed in recent years. Healthcare decision makers—regulatory and health technology …

The number of prostate cancer survivors is rapidly growing in the Western world. As a result
of better oncologic outcomes, more patients are living longer with the adverse effects of …

Background The taxanes docetaxel and cabazitaxel prolong overall survival for men with
metastatic castration-resistant prostate cancer (mCRPC), with cabazitaxel approved in the …